URGN
UroGen Pharma·NASDAQ
--
--(--)
--
--(--)
6.94 / 10
Outperform
Liquidity flow evaluation: 7.67/10 demonstrating robust fund flow characteristics. Optimistic Small and Medium patterns are mitigated by pessimistic overall, block, Large, and Extra-large indicators, pointing to positive flow perspective. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(100.0%) across 2 coverage providers, supported by 6.20 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-23
InstitutionD. Boral Capital
Times predicted16
Historical Win Rate43.8%
What is the market sentiment for URGN?
- URGN holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.94/10 (Outperform).
